Two Sigma Investments, LP Humanigen, Inc Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.13 - $0.2 $1,982 - $3,049	-15,248 Reduced 9.02%	153,889 $23,000
Q1 2023 May 15, 2023	BUY	$0.12 - $0.23 $8,348 - $16,000	69,567 Added 69.87%	169,137 $23,000
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.2 $7,143 - $15,873	79,369 Added 392.9%	99,570 $11,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $3,030 - $61,007	20,201 New	20,201 $4,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $40,080 - $75,834	-22,773 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $224,526 - $492,470	-124,048 Reduced 84.49%	22,773 $69,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $537,364 - $1.21 Million	146,821 New	146,821 $546,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.